###begin article-title 0
Milk fat globule epidermal growth factor-8 blockade triggers tumor destruction through coordinated cell-autonomous and immune-mediated mechanisms
###end article-title 0
###begin p 1
###xml 325 326 321 322 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 330 331 323 324 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 908 909 901 902 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 670 675 <span type="species:ncbi:10090">mouse</span>
Carcinogenesis reflects the dynamic interplay of transformed cells and normal host elements, but cancer treatments typically target each compartment separately. Within the tumor microenvironment, the secreted protein milk fat globule epidermal growth factor-8 (MFG-E8) stimulates disease progression through coordinated alphavbeta3 integrin signaling in tumor and host cells. MFG-E8 enhances tumor cell survival, invasion, and angiogenesis, and contributes to local immune suppression. We show that systemic MFG-E8 blockade cooperates with cytotoxic chemotherapy, molecularly targeted therapy, and radiation therapy to induce destruction of various types of established mouse tumors. The combination treatments evoke extensive tumor cell apoptosis that is coupled to efficient dendritic cell cross-presentation of dying tumor cells. This linkage engenders potent antitumor effector T cells but inhibits FoxP3+ T reg cells, thereby achieving long-term protective immunity. Collectively, these findings suggest that systemic MFG-E8 blockade might intensify the antitumor activities of existing therapeutic regimens through coordinated cell-autonomous and immune-mediated mechanisms.
###end p 1
###begin p 2
###xml 178 179 178 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">1</xref>
###xml 346 347 346 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">2</xref>
###xml 348 349 348 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">4</xref>
###xml 538 539 527 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">5</xref>
###xml 540 541 529 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">8</xref>
Cancer pathogenesis involves not only the cell-autonomous defects that arise from alterations in oncogenes and tumor suppressors but also the impact of host antitumor responses (1). Cancer cells that have escaped immune control are selected for the ability to exploit factors present in the tumor microenvironment to further disease progression (2-4). Among this array of soluble moieties, inflammatory cytokines including TNF-alpha, IL-6, and IL-1beta play key roles through triggering NF-kappaB-, STAT-3-, and MyD88-dependent pathways (5-8).
###end p 2
###begin p 3
###xml 143 144 143 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 429 430 425 426 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 434 435 427 428 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 445 446 434 435 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 450 451 436 437 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 463 464 449 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 465 467 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">12</xref>
###xml 677 678 660 661 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 692 694 675 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 834 835 817 818 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 843 844 826 827 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 183 187 <span type="species:ncbi:10090">mice</span>
GM-CSF is another cytokine frequently produced in the tumor microenvironment, where it may contribute to either tumor protection or promotion (9). Through studies of GM-CSF-deficient mice, we identified milk fat globule epidermal growth factor-8 (MFG-E8) as a critical determinant of the pro- and antiinflammatory activities of the cytokine (10). MFG-E8 is a secreted phosphatidylserine-binding protein that signals through alphavbeta3 and alphavbeta5 integrins (9-12). Under steady-state conditions, GM-CSF induces MFG-E8 expression in mononuclear phagocytes, enabling the efficient uptake of apoptotic cells, the production of TGF-beta and CCL22, and the maintenance of FoxP3+ T reg cells (10). Under conditions of cellular stress, however, the ligation of Toll-like receptors dampens MFG-E8 expression, whereupon GM-CSF elicits CD4+ and CD8+ effector T cells through an MFG-E8-independent pathway. Thus, the levels of MFG-E8 present in the tumor microenvironment might modulate the functions of GM-CSF during carcinogenesis.
###end p 3
###begin p 4
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">12</xref>
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">13</xref>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">12</xref>
###xml 600 601 600 601 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 669 670 669 670 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 256 261 <span type="species:ncbi:10090">mouse</span>
In malignant melanoma, MFG-E8 expression is increased in tumor cells and/or infiltrating myeloid elements upon progression to the vertical growth phase, the stage in which melanoma cells acquire the competence for invasion and dissemination (12, 13). In a mouse melanoma model, MFG-E8 augmented tumorigenicity and metastatic capability through Akt- and Twist-dependent mechanisms (12). MFG-E8 enhanced melanoma cell resistance to apoptosis, induced an epithelial-to-mesenchymal transition, and stimulated invasion and angiogenesis. MFG-E8 also contributed to local immune suppression by evoking FoxP3+ T reg cell infiltrates and suppressing Th1 reactions and NK and CD8+ T cell cytotoxicity.
###end p 4
###begin p 5
###xml 67 69 67 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">14</xref>
###xml 71 73 71 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">15</xref>
###xml 618 620 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 622 624 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">12</xref>
###xml 911 916 <span type="species:ncbi:10090">mouse</span>
Because MFG-E8 is expressed at high levels in diverse tumor types (14, 15), including melanoma, this soluble protein might serve as a general target for cancer therapy. In contrast to most oncologic treatments, which primarily address either the tumor or host separately, MFG-E8 antagonists might affect both compartments. Indeed, shRNA knockdowns of MFG-E8 sensitized tumor cells to cytotoxic agents and small molecule inhibitors of receptor tyrosine kinases in vitro, whereas MFG-E8 blockade with a dominant-negative mutant potentiated tumor immunity generated with irradiated, GM-CSF-secreting tumor cell vaccines (10, 12). Based on these results, we hypothesized that systemic targeting of MFG-E8 might contribute to tumor destruction in several complementary ways. In this paper, we show that antibodies to MFG-E8 cooperate with conventional cancer therapies to effectuate sustained control of established mouse tumors through the coupling of cell-autonomous and host-mediated pathways.
###end p 5
###begin title 6
RESULTS
###end title 6
###begin title 7
Combinatorial therapy with systemic MFG-E8 blockade
###end title 7
###begin p 8
###xml 268 269 256 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 389 391 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">16</xref>
###xml 467 475 455 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 A</xref>
###xml 515 517 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">17</xref>
###xml 749 751 737 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">18</xref>
###xml 781 789 769 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 B</xref>
###xml 170 174 <span type="species:ncbi:10090">mice</span>
###xml 358 366 <span type="species:ncbi:9606">patients</span>
###xml 712 718 <span type="species:ncbi:9986">rabbit</span>
To explore the therapeutic potential of anti-MFG-E8 antibodies, we first characterized the moderately immunogenic MC38 colon carcinoma model that is syngeneic to C57BL/6 mice. At 10 d after intradermal inoculation, when tumors were well established (approximately25 mm2), the systemic administration of gemcitabine, a cytotoxic agent with modest activity in patients with colon carcinoma (16), afforded a small delay in MC38 tumor growth in a dose-dependent fashion (Fig. 1 A). Although a blocking anti-MFG-E8 mAb (17) displayed minimal antitumor activity when infused alone, combination treatment with gemcitabine resulted in tumor regressions that were sustained throughout the duration of the study (4 mo). A rabbit polyclonal anti-MFG-E8 serum (18) showed comparable efficacy (Fig. 1 B), whereas an isotype control mAb was inactive (not depicted), establishing the specificity of the response. Synergistic antitumor effects were also obtained when the anti-MFG-E8 antibodies were administered beginning 3 or 7 d after gemcitabine but not when infused before chemotherapy, indicating that the sequence of the combination was important for activity ().
###end p 8
###begin p 9
###xml 0 90 0 90 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MFG-E8 antibody blockade synergizes with cytotoxic therapies to mediate tumor destruction.</bold>
###xml 129 130 129 130 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 651 652 651 652 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 256 262 <span type="species:ncbi:9986">rabbit</span>
###xml 785 789 <span type="species:ncbi:10090">mice</span>
MFG-E8 antibody blockade synergizes with cytotoxic therapies to mediate tumor destruction. (A) Established MC38 carcinomas (25 mm2) were treated with systemic gemcitabine (GEM) and/or an anti-MFG-E8 mAb, as indicated. (B) Same conditions as in A, but with rabbit anti-MFG-E8 sera. (C) Established MC38 carcinomas were treated with 5-FU or CPT-11 with or without anti-MFG-E8 mAb. (D) Established MC38 carcinomas were treated with anti-VEGFR-2 mAb DC101 or EGFR-TKI AG490 with or without anti-MFG-E8 mAb. (E) Established MC38 tumors were treated with local irradiation (XRT) with or without systemic anti-MFG-E8 mAb. (F) Established B16 melanomas (25 mm2) were treated with systemic doxorubicin, etoposide, or GEM with or without anti-MFG-E8 mAb. Each experiment was performed with five mice per group, and similar results were observed for each panel in five independent experiments. Shown are the means +/- SEM per cohort for a representative experiment. *, P < 0.05 between a treatment group and control.
###end p 9
###begin p 10
###xml 112 120 112 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 C</xref>
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">16</xref>
###xml 532 540 532 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 D</xref>
###xml 708 716 708 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 E</xref>
###xml 1018 1026 1018 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 F</xref>
###xml 195 203 <span type="species:ncbi:9606">patients</span>
Systemic anti-MFG-E8 antibodies similarly enhanced the therapeutic potency of 5-fluorouracil (5-FU) and CPT-11 (Fig. 1 C), two agents frequently used in the treatment of advanced colon carcinoma patients (16). As with gemcitabine, these combination therapies achieved prolonged tumor control, in contrast to the limited impact of individual agents. MFG-E8 blockade also intensified the activity of an epidermal growth factor receptor tyrosine kinase inhibitor and an antivascular endothelial growth factor receptor-2 (VEGFR-2) mAb (Fig. 1 D). Additionally, a short course of radiation therapy directed toward subcutaneous MC38 lesions was rendered more efficacious when combined with anti-MFG-E8 antibodies (Fig. 1 E). Synergistic effects of anti-MFG-E8 antibodies and chemotherapy were similarly observed in the poorly immunogenic B16 melanoma model. In this system, combinations of MFG-E8 blockade with doxorubicin, etoposide, or dacarbazine achieved significant tumor control, although gemcitabine proved inactive (Fig. 1 F and not depicted). Moreover, the combined administration of anti-MFG-E8 antibodies and doxorubicin also triggered the destruction of established EL-4 thymomas (). Collectively, these experiments reveal the ability of systemic MFG-E8 blockade to intensify the antitumor effects of conventional oncologic therapies in diverse tumor models.
###end p 10
###begin title 11
MFG-E8 blockade enhances drug-induced apoptosis
###end title 11
###begin p 12
###xml 297 298 293 294 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 302 303 295 296 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 385 387 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">12</xref>
###xml 701 716 694 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2, A and B</xref>
###xml 828 836 817 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 C</xref>
###xml 1153 1161 1142 1150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 D</xref>
Because standard cancer treatments displayed only modest single-agent activity against various types of tumors, we wondered whether the anti-MFG-E8 antibodies might modulate tumor cell killing. In this context, we previously showed that MFG-E8 triggered Akt activation in tumor cells through alphavbeta3 integrin signaling, which resulted in an attenuation of etoposide-induced death (12). In accordance with these findings, MFG-E8 was not detectable in MC38 and B16 cells at baseline, whereas cells that survived an overnight exposure to diverse chemotherapeutic drugs manifested significant MFG-E8 expression, which was evident intracellularly, at the surface membrane, and in culture supernatants (Fig. 2, A and B; and not depicted). gamma irradiation also induced MFG-E8 surface expression on EL-4 thymoma (EG.7-OVA) cells (Fig. 2 C). Furthermore, stable drug-resistant variants of MC38 cells, which were generated through prolonged exposure to escalating concentrations of gemcitabine, CPT-11, or 5-FU in vitro, and similarly derived doxorubicin-resistant B16 cells demonstrated much higher levels of MFG-E8 compared with the parental tumor cells (Fig. 2 D and not depicted).
###end p 12
###begin p 13
###xml 0 42 0 42 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drug-resistant tumor cells express MFG-E8.</bold>
###xml 227 228 227 228 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 245 246 245 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 673 674 669 670 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 691 692 687 688 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1158 1159 1154 1155 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1257 1263 1253 1259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1</xref>
Drug-resistant tumor cells express MFG-E8. (A) MC38 carcinoma and B16 melanoma cells were treated with various cytotoxic agents under serum-free condition for 24 h, and intracellular MFG-E8 expression in viable cells (annexin V-/propidium iodide-) was determined with flow cytometry. The shaded and open histograms represent the levels of expression on untreated and treated cells, respectively. Gemcitabine (GEM) and 5-FU accomplished minimal killing of B16 cells (not depicted). (B) MFG-E8 levels in culture supernatants from A were measured with ELISA. (C) EL-4 thymoma cells were treated with gamma irradiation (100 Gy), and MFG-E8 expression in viable cells (annexin V-/propidium iodide-) was determined with flow cytometry. (D) Stable drug-resistant variants of MC38 were generated and tested for MFG-E8 expression with flow cytometry (shaded histogram). The staining with isotype control antibodies is also shown. (E) MC38 carcinoma cells were exposed to GEM or 5-FU in the presence of anti-MFG-E8 mAb or isotype control as in A, and cell viability was determined with flow cytometry (percentages are shown). (F) Established MC38 and B16 tumors (25 mm2) were treated with GEM or dacarbazine, respectively, with or with systemic anti-MFG-E8 mAb as in Fig. 1. 4 d after completion of therapy, tumor homogenates were prepared and assayed for caspase 3 activation with ELISA. Presented data are representative of three independent experiments with similar results. Means +/- SEM are shown in B and F. *, P < 0.05 between the treatment and control.
###end p 13
###begin p 14
###xml 267 275 267 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 E</xref>
###xml 803 811 803 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 F</xref>
###xml 1248 1250 1248 1250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">18</xref>
###xml 294 300 <span type="species:ncbi:9986">rabbit</span>
###xml 631 635 <span type="species:ncbi:10090">mice</span>
###xml 765 769 <span type="species:ncbi:10090">mice</span>
Consistent with an antiapoptotic function for surface and/or secreted MFG-E8, the addition of anti-MFG-E8 mAbs but not irrelevant control antibodies potentiated the killing of MC38 cells with gemcitabine and 5-FU, as revealed by the enhanced expression of annexin V (Fig. 2 E). The addition of rabbit polyclonal anti-MFG-E8 serum manifested comparable effects (unpublished data). The induction of apoptosis with the combined therapy also resulted in a loss of mitochondrial membrane potential (unpublished data). Moreover, the combination therapies triggered increased levels of tumor apoptosis in vivo. MC38 tumors harvested from mice that received gemcitabine plus anti-MFG-E8 antibodies showed enhanced caspase 3 activation as compared with tumors isolated from mice treated with either agent alone (Fig. 2 F). Similarly, B16 melanomas manifested elevated caspase 3 activation after combined dacarbazine and MFG-E8 blockade. These results support the idea that MFG-E8 blockade compromises tumor cell viability in a cell-autonomous fashion, although the increased caspase activation in vivo might partially reflect the death of stromal elements within the tumor microenvironment. The anti-MFG-E8 antibodies may also attenuate tumor angiogenesis (18), which might contribute to tumor cell death as well. Collectively, these results reveal a role for MFG-E8 in mediating resistance to cytotoxic therapy and suggest that anti-MFG-E8 antibodies might serve as a complementary strategy to intensify drug-induced tumor cell killing.
###end p 14
###begin title 15
Combinatorial therapy with MFG-E8 blockade stimulates T cell immunity
###end title 15
###begin p 16
###xml 59 61 59 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 411 419 411 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 A</xref>
###xml 483 484 483 484 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 511 512 511 512 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 747 748 747 748 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 767 775 767 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 B</xref>
###xml 1181 1189 1181 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 C</xref>
###xml 405 409 <span type="species:ncbi:10090">mice</span>
###xml 567 571 <span type="species:ncbi:10090">mice</span>
###xml 1063 1067 <span type="species:ncbi:10090">mice</span>
Because MFG-E8 plays a key role in T reg cell homeostasis (10), we investigated whether the antitumor activities of combined chemotherapy and MFG-E8 blockade might also involve host immunity. In accordance with this idea, anti-MFG-E8 antibodies failed to increase the minimal killing of MC38 cells achieved with gemcitabine in immunodeficient nonobese diabetic-severe combined immunodeficiency (NOD-SCID) mice (Fig. 3 A). Moreover, antibody depletion experiments established that CD8+ and to a lesser extent CD4+ T cells, but not NK cells, were required in wild-type mice for tumor destruction with the combination therapy, although the antitumor effects became significant compared with gemcitabine alone 40 d after combined therapy even with CD8+ T cell depletion (Fig. 3 B). These findings suggest that the cell autonomous modes of tumor cell killing with MFG-E8 blockade are not sufficient to maintain durable control of the established cancers. Consistent with a key role for T cells in the generation of long-lived and specific protective immunity, treated mice rejected a subsequent lethal challenge with MC38 tumor cells but not B16 melanoma or MCA-205 fibrosarcoma cells (Fig. 3 C).
###end p 16
###begin p 17
###xml 0 93 0 93 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">The therapeutic activity of MFG-E8 antibody blockade and chemotherapy involves host immunity.</bold>
###xml 156 157 156 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 299 300 299 300 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 305 306 305 306 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 316 317 316 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 107 111 <span type="species:ncbi:10090">mice</span>
###xml 269 273 <span type="species:ncbi:10090">mice</span>
###xml 428 432 <span type="species:ncbi:10090">mice</span>
###xml 686 690 <span type="species:ncbi:10090">mice</span>
The therapeutic activity of MFG-E8 antibody blockade and chemotherapy involves host immunity. (A) NOD-SCID mice harboring established MC38 carcinomas (25 mm2) were treated with systemic GEM and anti-MFG-E8 mAb. (B) Established MC38 carcinomas bearing wild-type C57BL/6 mice that were depleted of CD4+, CD8+, or NK1.1+ cells with antibodies were treated with systemic gemcitabine (GEM) and anti-MFG-E8 mAb. (C) Wild-type C57BL/6 mice that had rejected established MC38 carcinomas with systemic GEM and anti-MFG-E8 mAb showed specific long-term protective immunity against subsequent challenge with MC38 cells during the follow-up period (>200 d). Each experiment was performed with five mice per group, and similar results were observed for each panel in three independent experiments. Shown are the means +/- SEM for each cohort in a representative experiment. *, P < 0.05 between the treatment and control.
###end p 17
###begin p 18
###xml 174 175 174 175 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 183 184 183 184 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 346 347 346 347 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 361 369 361 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 A</xref>
###xml 536 544 536 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 A</xref>
###xml 864 866 864 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 868 870 868 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">12</xref>
To characterize the T cell responses stimulated with treatment, we isolated tumor-infiltrating lymphocytes from regressing MC38 lesions. Although the proportions of total CD4+ and CD8+ T cells did not vary as a function of therapy, anti-MFG-E8 antibodies alone or in combination with CPT-11 significantly reduced the numbers of intratumoral Foxp3+ T reg cells (Fig. 4 A). Although chemotherapy alone had no impact on T reg cell numbers, combined treatment with anti-MFG-E8 antibodies decreased T reg cell numbers in the spleen as well (Fig. 4 A). The T reg cells that were recovered after MFG-E8 blockade, however, did not manifest impaired function on a per cell basis, as assessed in standard in vitro suppression assays (unpublished data). These findings extend our earlier demonstration that MFG-E8 is an important determinant of antitumor T reg cell numbers (10, 12).
###end p 18
###begin p 19
###xml 108 109 108 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 0 122 0 122 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Combination MFG-E8 antibody blockade and chemotherapy enhances antitumor effector T cells and inhibits FoxP3<sup>+</sup> T reg cells.</bold>
###xml 267 268 267 268 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 271 272 271 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 279 280 279 280 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 283 284 283 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 659 661 653 655 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">51</sup>
###xml 181 185 <span type="species:ncbi:10090">mice</span>
###xml 471 475 <span type="species:ncbi:10090">mice</span>
###xml 578 582 <span type="species:ncbi:10090">mice</span>
###xml 863 867 <span type="species:ncbi:10090">mice</span>
Combination MFG-E8 antibody blockade and chemotherapy enhances antitumor effector T cells and inhibits FoxP3+ T reg cells. Tumor-infiltrating lymphocytes (TILs) were harvested from mice bearing MC38 tumors 5 d after the indicated treatment. The TILs were gated as CD3+CD4+ or CD3+CD8+ T cells, and assayed for (A) FoxP3, (B) IFN-gamma, and (C) CD44 expression with flow cytometry (percentages are shown). Representative stainings are presented. The means +/- SEM for six mice per group are shown in the adjacent panels. (D) Draining lymph nodes were harvested from MC38-bearing mice after the indicated treatments and evaluated for cytotoxic activity against 51Cr-labeled MC38 and B16 targets in vitro. The percent specific lysis is presented. Each experiment was independently performed four times. The means +/- SEM at an effector/target ratio of 100:1 for six mice per group are shown in the adjacent panels. *, P < 0.05 between the treatment and control.
###end p 19
###begin p 20
###xml 87 88 87 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 96 97 96 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 252 263 248 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4, B&#8211;D</xref>
The combination treatment, but not anti-MFG-E8 antibodies alone, markedly increased CD4+ and CD8+ effector T cell activation and function. This stimulation resulted in high levels of surface CD44, IFN-gamma production, and tumor-specific cytotoxicity (Fig. 4, B-D). The combination therapy also augmented the total levels of circulating IgG2a and IgG2b antibodies, which might contribute to tumor destruction through Fc-dependent cytotoxicity (). These results highlight the synergy between systemic MFG-E8 blockade and chemotherapy for boosting multiple antitumor effector mechanisms.
###end p 20
###begin title 21
Anti-MFG-E8 antibodies enhance dendritic cell cross-presentation of tumor antigens
###end title 21
###begin p 22
###xml 81 83 81 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 85 87 85 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">19</xref>
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">21</xref>
###xml 281 282 281 282 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 287 288 287 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 332 333 332 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 338 339 338 339 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 418 419 418 419 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 426 427 426 427 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 549 557 549 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 A</xref>
Because MFG-E8 promotes the uptake of apoptotic cells by mononuclear phagocytes (10, 19-21), we next characterized the impact of chemotherapy and MFG-E8 blockade on antigen-presenting cells. Although the combination treatment did not influence the proportions of macrophages (CD11b+ Gr-1-) or myeloid-derived suppressor cells (CD11b+ Gr-1+) that were isolated from regressing MC38 colon tumors (), the numbers of CD11b+, CD11c+ dendritic cells were significantly increased, and these cells expressed high levels of the co-stimulatory molecule CD86 (Fig. 5 A). As bone marrow-derived dendritic cells (BMDCs) efficiently phagocytosed chemotherapy-exposed MC38 and B16 cells in vitro (), our analysis of the tumor infiltrates raised the possibility that dendritic cell capture of tumor cells in situ might be important for T cell priming.
###end p 22
###begin p 23
###xml 0 86 0 86 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Anti&#8211;MFG-E8 antibodies enhance dendritic cell cross-presentation of dying tumor cells.</bold>
###xml 209 210 209 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 219 220 219 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 713 714 707 708 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 988 989 980 981 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1108 1109 1092 1093 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1274 1275 1256 1257 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1493 1494 1471 1472 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 136 140 <span type="species:ncbi:10090">mice</span>
###xml 496 500 <span type="species:ncbi:10090">mice</span>
###xml 1306 1311 <span type="species:ncbi:10090">mouse</span>
###xml 1352 1356 <span type="species:ncbi:10090">mice</span>
Anti-MFG-E8 antibodies enhance dendritic cell cross-presentation of dying tumor cells. (A) Tumor-infiltrating cells were harvested from mice harboring MC38 carcinomas 4 d after the indicated treatment. The CD3+ and B220+ lymphocytes were excluded by gating, and the remaining forward/side scatter high cells were analyzed for CD11c, CD11b, and CD86 with flow cytometry (percentages are shown). Similar results were observed in three experiments. Shown to the right are the means +/- SEM for five mice per group. *, P < 0.05. (B) BMDCs were co-cultured with PKH26-labeled EG.7-OVA cells (with or without opsonization with anti-MFG-E8 mAbs) and evaluated for phagocytosis. The impact of blocking antibodies to alphav integrins and Fc receptors was determined (percentages are shown). Similar results were observed in three experiments, and the means +/- SEM are shown. *, P < 0.05. (C) BMDCs that were loaded with EG.7-OVA cells as in B were co-cultured with OVA-specific TCR transgenic CD4+ T cells, and IFN-gamma production was evaluated with flow cytometry (percentages are shown). The effects of anti-alphav integrin and Fc receptor antibodies are shown. Similar results were observed in three experiments, and the means +/- SEM are shown to the right. *, P < 0.05. (D) 106 irradiated EG.7-OVA cells per mouse were injected into the footpads of OT-I mice with anti-MFG-E8, anti-FcgammaR, and isotype control antibodies as indicated. The draining lymph nodes were harvested after 5 d, and CD8+ T cell IFN-gamma production was determined with flow cytometry (percentages are shown). Similar results were observed in three experiments. Shown are the means +/- SEM. *, P < 0.05.
###end p 23
###begin p 24
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib22">22</xref>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">23</xref>
###xml 404 405 400 401 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 511 519 507 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 B</xref>
###xml 693 694 685 686 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 854 855 842 843 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 859 860 844 845 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 866 867 847 848 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 871 872 849 850 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 194 198 <span type="species:ncbi:10090">mice</span>
To study the impact of anti-MFG-E8 antibodies on dendritic cell cross-presentation in more detail, we used EL-4 thymoma cells engineered to express OVA (EG.7-OVA) (22) and the syngeneic C57BL/6 mice harboring a transgenic TCR specific for an MHC class II-presented OVA peptide (OT-II) (23). BMDCs efficiently ingested irradiated EG.7-OVA cells, and this was only minimally blocked by an antibody to alphav integrins or MFG-E8, indicating that this pathway was not required for tumor cell uptake in this system (Fig. 5 B and not depicted). Although anti-MFG-E8 antibodies did not affect the overall phagocytosis of irradiated EG.7-OVA cells, a blocking antibody to Fc receptors but not to alphav integrins partially attenuated uptake. These results reveal that anti-MFG-E8 antibodies switch the receptor for MFG-E8-mediated tumor cell ingestion from alphavbeta3/alphavbeta5 integrins to Fc receptors.
###end p 24
###begin p 25
###xml 86 88 86 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">24</xref>
###xml 217 218 217 218 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 291 299 287 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 C</xref>
###xml 423 424 415 416 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 606 614 598 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 C</xref>
###xml 712 713 704 705 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Consistent with the ability of activating Fc receptors to trigger immune stimulation (24), the opsonization of EG.7-OVA cells with anti-MFG-E8 antibodies enhanced dendritic cell stimulation of OT-II TCR transgenic CD4+ T cells. This activation resulted in increased production of IFN-gamma (Fig. 5 C) but not IL-4 or IL-17 (not depicted). In contrast, anti-Fc receptor antibodies inhibited cross-priming, whereas anti-alphav integrin antibodies augmented T cell responses when either irradiated EG.7-OVA cells alone or anti-MFG-E8 antibody opsonized, irradiated EG.7-OVA cells were fed to dendritic cells (Fig. 5 C). The anti-MFG-E8 antibodies also increased cross-presentation to MHC class I-restricted OT-I CD8+ T cells, resulting in increased IFN-gamma production (). Collectively, these findings suggest that MFG-E8 blockade enhances Th1 antitumor responses.
###end p 25
###begin p 26
###xml 488 489 484 485 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 616 624 604 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 D</xref>
###xml 717 718 705 706 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 186 190 <span type="species:ncbi:10090">mice</span>
To further examine the importance of MFG-E8 antibody-mediated cross-priming in vivo, we injected irradiated EG.7-OVA cells together with anti-MFG-E8 antibodies into the footpads of OT-I mice and measured OVA-specific T cell responses in the draining lymph nodes 5 d later. In some experiments, blocking anti-FcgammaR antibodies were coadministered to evaluate the role of FcR-mediated uptake for antigen presentation. Although the injection of anti-MFG-E8 antibodies enhanced specific CD8+ T cell IFN-gamma production, the concurrent administration of anti-FcgammaR antibodies substantially inhibited this response (Fig. 5 D). These results indicate that MFG-E8 blockade promotes cross-priming of antigen-specific CD8+ T cells primarily through FcR-mediated antigen uptake.
###end p 26
###begin title 27
MFG-E8 modulates dendritic cell cytokine production
###end title 27
###begin p 28
###xml 347 355 343 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 A</xref>
###xml 439 440 431 432 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 513 514 501 502 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 518 519 503 504 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 529 530 510 511 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 534 535 512 513 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
To further clarify the mechanisms underlying T cell stimulation, we examined the impact of MFG-E8 on dendritic cell cytokine production after the uptake of dying tumor cells. The addition of rMFG-E8 protein increased dendritic cell IL-10 secretion, whereas anti-MFG-E8 antibodies reduced IL-10 but enhanced IL-12, IL-23, and TNF-alpha production (Fig. 6 A). The effects of MFG-E8 on cytokine profiles were blocked with the RMV-7 anti-alphav integrin antibody (unpublished data), confirming the importance of alphavbeta3 and alphavbeta5 integrins in this response.
###end p 28
###begin p 29
###xml 0 74 0 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Anti&#8211;MFG-E8 antibodies modulate antigen-presenting cell cytokine profiles.</bold>
###xml 357 358 355 356 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 444 452 442 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 A</xref>
###xml 723 724 719 720 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 302 306 <span type="species:ncbi:10090">mice</span>
###xml 491 495 <span type="species:ncbi:10090">mice</span>
###xml 612 616 <span type="species:ncbi:10090">mice</span>
###xml 662 666 <span type="species:ncbi:10090">mice</span>
###xml 757 761 <span type="species:ncbi:10090">mice</span>
Anti-MFG-E8 antibodies modulate antigen-presenting cell cytokine profiles. (A) BMDCs were treated with recombinant MFG-E8 or anti-MFG-E8 mAbs, and cytokine production was determined with ELISA. Shown are the means +/- SEM for three experiments. *, P < 0.05. (B) C57BL/6 wild-type or IL-12p35-deficient mice harboring established MC38 colon carcinomas (25 mm2) were treated with systemic gemcitabine with or without anti-MFG-E8 mAb, as shown in Fig. 1 A. Shown are the means +/- SEM for five mice per group. Similar results were observed in a second experiment. *, P < 0.05 between treated wild-type and IL-12 KO mice. (C) BMDCs from wild-type or IL-12-deficient mice were loaded with EG.7-OVA cells and co-cultured with CD4+ T cells obtained from wild-type mice that were immunized with EG.7-OVA cells (five times). IFN-gamma production was evaluated by flow cytometry (percentages are shown). Similar results were observed in a second experiment.
###end p 29
###begin p 30
###xml 327 335 327 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 B</xref>
###xml 431 432 431 432 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 535 543 535 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 C</xref>
###xml 111 115 <span type="species:ncbi:10090">mice</span>
###xml 288 292 <span type="species:ncbi:10090">mice</span>
To address the role of IL-12 in the immune stimulation with anti-MFG-E8 antibodies, we used IL-12p35-deficient mice in a series of in vivo and in vitro studies. The efficacy of anti-MFG-E8 antibodies and CPT-11 treatment against MC38 colon tumors was partially reduced in IL-12-deficient mice compared with wild-type controls (Fig. 6 B). Moreover, the anti-MFG-E8 antibody-mediated cross-presentation of EG.7-OVA cells to OT-II CD4+ T cells was slightly decreased with IL-12-deficient dendritic cells compared with wild-type controls (Fig. 6 C). These results suggest that IL-12 contributes to the anti-MFG-E8 antibody-triggered immunostimulation, but other cytokines and/or cell-surface molecules also play important roles.
###end p 30
###begin title 31
DISCUSSION
###end title 31
###begin p 32
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">25</xref>
###xml 428 430 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">26</xref>
###xml 432 434 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">27</xref>
###xml 797 799 797 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">28</xref>
###xml 504 512 <span type="species:ncbi:9606">patients</span>
Although substantial evidence demonstrates that cross talk between tumor cells and normal host elements is critical to carcinogenesis (25), most cancer therapies primarily target individual compartments. Small molecule inhibitors of oncogenic tyrosine kinases and antibody blockade of VEGF serve as prototypes of rationally designed agents that antagonize major pathogenic mechanisms in cancer cells and the host, respectively (26, 27). Although these treatments afford important clinical benefits, most patients achieve only partial responses and eventually succumb to progressive disease caused by the emergence of drug-resistant variants. However, analogous to the ways in which antimicrobial agents cooperate with host reactions to effectuate sterilizing immunity for some serious infections (28), cancer treatments might be significantly improved through concurrently targeting the tumor and host. The results presented in this paper illustrate the potential for systemic MFG-E8 antibody blockade in combination with conventional oncologic therapies to accomplish this dual targeting.
###end p 32
###begin p 33
###xml 60 61 56 57 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 65 66 58 59 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 153 155 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">12</xref>
###xml 1178 1180 1171 1173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">14</xref>
###xml 1182 1184 1175 1177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">18</xref>
MFG-E8 promotes cancer progression through coordinated alphavbeta3 integrin signaling in tumor cells, vascular elements, and infiltrating myeloid cells (12). Although the administration of anti-MFG-E8 antibodies alone resulted in only modest tumor destruction and immune stimulation, the coupling of drug-induced tumor cell death to MFG-E8 blockade effectuated the sustained regressions of established colon carcinomas, melanomas, and lymphomas. A key component of this therapeutic synergy is the ability of anti-MFG-E8 antibodies to attenuate tumor cell resistance to cytotoxic treatments, likely because of the inhibition of Akt activation. Some degree of intrinsic tumor cell sensitivity to the cytotoxic agent appears necessary for this enhancement, though, because gemcitabine, which failed to provoke B16 cell death in vitro (unpublished data), proved inactive in vivo in combination with MFG-E8 blockade. An additional mechanism by which anti-MFG-E8 antibodies might increase tumor cell killing, particularly in conjunction with anti-VEGFR-2 antibodies, may involve a more robust inhibition of the tumor blood supply, as MFG-E8 is required for VEGF-induced angiogenesis (14, 18). Moreover, knockdown of MFG-E8 in MC38 carcinoma cells exposed to chemotherapy also reduced VEGF production (unpublished data).
###end p 33
###begin p 34
###xml 247 248 243 244 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 252 253 245 246 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 456 457 445 446 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 545 547 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib29">29</xref>
###xml 590 592 579 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">12</xref>
###xml 635 637 620 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">30</xref>
###xml 1141 1143 1122 1124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib31">31</xref>
###xml 1260 1261 1241 1242 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1269 1270 1250 1251 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1310 1311 1291 1292 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1690 1692 1671 1673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib32">32</xref>
###xml 1694 1696 1675 1677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">33</xref>
###xml 406 410 <span type="species:ncbi:10090">mice</span>
###xml 849 853 <span type="species:ncbi:10090">mice</span>
Upon the induction of tumor cell death in vivo with cytotoxic treatments, MFG-E8 blockade favored the establishment of an immunogenic tumor microenvironment. This conversion reflected the dual capacity of anti-MFG-E8 antibodies to antagonize alphavbeta3 integrin-driven immune suppression and to promote efficient Fc receptor-mediated dendritic cell cross-presentation. In this context, recent analysis of mice harboring a myeloid cell-specific KO of alphav integrins has underscored the importance of this receptor in attenuating inflammation (29), perhaps through the induction of Twist (12), an antagonist of the NF-kappaB pathway (30). Consistent with these results, we found that MFG-E8 blockade resulted in increased IL-12 production. This proinflammatory cytokine contributed to tumor protection, as revealed through studies of p35-deficient mice, although other factors such as IL-23, TNF-alpha, and type I IFNs may play important roles as well. Accumulating evidence has also highlighted the ability of mAbs to opsonize tumor cells for efficient cross-presentation by dendritic cells, thereby engendering potent antitumor immunity (31). Collectively, these factors may promote the development of dense intratumoral infiltrates composed of abundant CD4+ and CD8+ effector T cells but only limited FoxP3+ T reg cells. It is tempting to speculate that this broad T cell response may suppress the emergence of drug-resistant tumor cells and mediate long-term protection against tumor recurrence. In accordance with this idea, previous experimental and clinical studies have shown that a high ratio of effector T cells to T reg cells is tightly linked with sustained tumor destruction (32, 33).
###end p 34
###begin p 35
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib34">34</xref>
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib36">36</xref>
###xml 430 431 430 431 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 450 452 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib37">37</xref>
###xml 662 664 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib38">38</xref>
###xml 666 668 666 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib39">39</xref>
Recent work has illustrated that some cytotoxic therapies, including anthracyclines and taxanes, may induce a form of immunogenic cell death in which the release of calreticulin and high mobility group box 1 from dying tumor cells serves as an innate activating signal (34-36). Cytotoxic therapies may additionally trigger the DNA damage response to up-regulate tumor cell expression of NKG2D ligands, thereby eliciting NK and CD8+ T cell responses (37). Moreover, agonistic antibodies to TNF-related apoptosis-inducing ligand receptors, which are frequently expressed on cancer cells, mediate potent antitumor effects in association with other immunotherapies (38, 39). Our results elucidate several novel antitumor mechanisms through which systemic MFG-E8 blockade may potentiate the efficacy of conventional oncologic therapies by coordinately targeting tumor cells and components of the tumor microenvironment. Perhaps the coupling of anti-MFG-E8 antibodies to tumor cell death might be considered a new strategy for in vivo cancer vaccination.
###end p 35
###begin title 36
MATERIALS AND METHODS
###end title 36
###begin title 37

###end title 37
###begin title 38
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice.
###end title 38
###begin p 39
###xml 216 218 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib40">40</xref>
###xml 220 222 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib41">41</xref>
###xml 44 48 <span type="species:ncbi:10090">mice</span>
###xml 176 180 <span type="species:ncbi:10090">mice</span>
C57BL/6, NOD-SCID, and OVA transgenic OT-II mice were obtained from SRL or the Jackson Laboratory and housed under specific pathogen-free conditions. OT-I and IL-12p35 gene KO mice were used as previously described (40, 41). All experiments were conducted according to a protocol approved by the review committee of animal research at the Institute of Medical Sciences of the University of Tokyo or Keio University School of Medicine.
###end p 39
###begin title 40
In vivo tumor challenges.
###end title 40
###begin p 41
###xml 87 88 87 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 222 223 222 223 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 873 874 873 874 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 1096 1098 1096 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">17</xref>
###xml 1100 1102 1100 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">18</xref>
###xml 1389 1391 1389 1391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib40">40</xref>
###xml 1393 1395 1393 1395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib42">42</xref>
###xml 47 51 <span type="species:ncbi:10090">mice</span>
###xml 229 233 <span type="species:ncbi:10090">mice</span>
###xml 303 307 <span type="species:ncbi:10090">mice</span>
###xml 671 675 <span type="species:ncbi:10090">mice</span>
###xml 787 791 <span type="species:ncbi:10090">mice</span>
###xml 963 969 <span type="species:ncbi:9986">rabbit</span>
###xml 1182 1186 <span type="species:ncbi:10090">mice</span>
6-wk-old C57BL/6, NOD-SCID, or IL-12 KO female mice were injected intradermally with 105 MC38 colon carcinoma, B16 melanoma, EL-4 thymoma, or MCA205 fibrosarcoma cells. After the tumors grew to an approximate size of 25 mm2, the mice were treated with various therapeutic regimens. For the MC38 tumors, mice received on days 10, 12, and 14 1 or 4 mg/ml gemcitabine, 5 mg/ml 5-FU, 1 mg/ml CPT-11, 40 mg/ml of the VEGFR-2 mAb DC101 (ImClone Systems), or the 40 mg/ml of the EGFR tyrosine kinase inhibitor AG490 (MERCK). In some experiments, tumors were treated with five daily doses of irradiation (3 Gy at a rate of 4 Gy/min) using an isolator system. For the B16 tumors, mice were treated with 5 mg/ml doxorubicin, 2 mg/ml etoposide, or gemcitabine as described. For EL-4 thymoma cells, mice were treated with 5 mg/ml doxorubicin, as described. A hamster mAb against MFG-E81 (at 2 mg/ml; MBL International), an isotype control immunoglobulin IgG2a, or 1 mg/ml of rabbit polyclonal anti-MFG-E8 sera (provided by C. Thery, Institut National de la Sante et de la Recherche Medicale, Paris, France) (17, 18) were administered concurrently with the cytotoxic therapies. In some studies, mice were also treated with depleting antibodies against CD4 (clone GK1.5), CD8 (clone 53-6.72), and NK1.1 (PK-136; American Type Culture Collection) at days -5, -3, and 0 relative to the cytotoxic therapy (40, 42). Tumor growth was monitored regularly and the products of the perpendicular diameters were recorded.
###end p 41
###begin title 42
Apoptosis assays.
###end title 42
###begin p 43
###xml 486 488 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 875 876 855 856 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 450 455 <span type="species:ncbi:10090">mouse</span>
Tumor cells were cultured in serum-free media and treated with various cytotoxic agents overnight with or without anti-MFG-E8 antibodies. To generate stable drug-resistant variants, MC38 cells were cultured in gradually increasing concentrations of gemcitabine (from 1 to 20 microg/ml) or CPT-11 (from 0.5 to 10 microg/ml) over approximately8 wk. MFG-E8 expression was measured by flow cytometry using the hamster anti-MFG-E8 mAb followed by an anti-mouse IgG, as previously described (10). Secreted MFG-E8 levels were measured with an ELISA according to the manufacture's instruction (R&D Systems). Cell death was determined with annexin V and propidium iodide staining, or DiOC6 labeling to quantify the mitochondrial membrane potential, according to the manufacturer's instructions (BD). To measure tumor apoptosis in vivo, we treated established MC38 or B16 tumors (25 mm2) with 10 mg/ml gemcitabine or dacarbazine with or without anti-MFG-E8 antibodies, harvested the tumors 4 d after therapy, and measured caspase 3 activation in tumor homogenates with a colorimetric assay kit (Invitrogen).
###end p 43
###begin title 44
Immune assays.
###end title 44
###begin p 45
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 351 353 347 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 522 524 518 520 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">51</sup>
Tumor-infiltrating lymphocytes were harvested with a cell gradient separation (Nocoprep; Axis-Shield), as previously described (10). Cell populations were characterized using mAbs against CD3, CD4, CD8, CD11b, CD11c, CD44, CD86, Gr-1, and Foxp3 (clone MF23). IFN-gamma production was measured by intracellular flow cytometry, as previously described (10). Cytotoxicity was measured by incubating lymphoid cells isolated from draining lymph nodes with irradiated MC38 cells for 96 h and then testing lytic activity against 51Cr-labeled MC38 and B16 targets. The percent lysis was calculated as (experimental - spontaneous)/(maximum - spontaneous) x 100, using 5% Triton X and medium alone for determination of the maximum and spontaneous counts.
###end p 45
###begin p 46
BMDCs were cultured from bone marrow precursors using GM-CSF-conditioned media for 7 d and were then treated with 100 ng/ml of recombinant MFG-E8 (R&D Systems), 20 microg/ml anti-MFG-E8 mAb (MBL International), or 20 microg/ml of polyclonal MFG-E8 antiserum overnight. Culture supernatants were evaluated for IL-12, IL-23, TNF-alpha, and IL-10 levels with ELISAs.
###end p 46
###begin title 47
Cross-priming assays.
###end title 47
###begin p 48
###xml 367 368 363 364 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 525 526 521 522 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 583 587 <span type="species:ncbi:10090">mice</span>
Day 7 BMDCs were also co-cultured with irradiated EG.7-OVA cells (1:10 ratio) that were labeled with PKH26 (Sigma-Aldrich) in 12-well round-bottom plates, and phagocytosis was determined with flow cytometry. In some experiments, the tumor cells were pretreated with 30 mg/ml anti-MFG-E8 mAb for 30 min before the co-culture. The impact of blocking antibodies to alphav integrins (clone RMV-7; Millipore) or Fc receptors (clone 2.4G2; BD) on tumor cell uptake was similarly evaluated. To antigen presentation by DCs, naive CD4+ T cells were isolated from the spleens of OT-I or OT-II mice by magnetic cell sorting (Miltenyi Biotec) and added to the tumor cell-loaded dendritic cells for 24 h. Intracellular IFN-gamma expression in T cells was then determined by flow cytometry.
###end p 48
###begin p 49
###xml 36 37 36 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 415 416 411 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 68 73 <span type="species:ncbi:10090">mouse</span>
###xml 114 118 <span type="species:ncbi:10090">mice</span>
###xml 244 248 <span type="species:ncbi:10090">mice</span>
For in vivo cross-priming assays, 106 irradiated EG.7-OVA cells per mouse were injected into the footpads of OT-I mice with 1 mg/ml anti-MFG-E8 mAb, 1 mg/ml anti-FcR blocking antibody (clone 2.4G2), or isotype control. 5 d after the challenge, mice were sacrificed, and the draining lymph node cells were isolated and cultured with 10 mg/ml MHC class I-restricted OVA peptides overnight. IFN-gamma production by CD8+ T cells was then determined by flow cytometry or ELISA using the culture supernatants.
###end p 49
###begin title 50
Statistical analysis.
###end title 50
###begin p 51
###xml 64 65 64 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Statistical analysis was performed using the unpaired Student's t test or one-way analysis of variance through all of the experimental procedures. Differences were considered significant when the p-value was <0.05.
###end p 51
###begin title 52
Online supplemental material.
###end title 52
###begin p 53
###xml 386 387 386 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 397 398 397 398 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 403 404 403 404 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Fig. S1 associates temporal relationships of anti-MFG-E8 antibody and chemotherapy administration in antitumor responses. Fig. S2 presents in vivo antitumor activities of anti-MFG-E8 antibody and doxorubicin against established EL-4 thymomas. Fig. S3 shows the humeral responses induced by in vivo treatment of anti-MFG-E8 antibody and chemotherapy. Fig. S4 shows the frequency of CD11b+ and CD11b+ Gr-1+myelid cells at tumors with the treatments. Fig. S5 suggests the in vitro phagocytosis of apoptotic tumor cells by BMDCs. In Fig. S6, the effect of anti-MFG-E8 antibody was examined in mediating in vitro cross-presentation of OVA antigen to OT-I T cells by BMDCs. Online supplemental material is available at .
###end p 53
###begin title 54
Supplementary Material
###end title 54
###begin title 55
[Supplemental Material Index]
###end title 55
###begin p 56
###xml 73 79 <span type="species:ncbi:9986">rabbit</span>
###xml 108 113 <span type="species:ncbi:10090">mouse</span>
We wish to thank Dr. Clotilde Thery for valuable advice in the making of rabbit polyclonal antibody against mouse MFG-E8; A. Kurose for her secretarial assistance; and S. Nakayama, A. Asami and R. Miyake for assistance with the in vivo tumor study, ELISA assay, and animal care. M. Jinushi, G. Dranoff, and H. Tahara were responsible for experimental design; M. Jinushi, M. Sato, and S. Nagai were responsible for the preparation and performance of experiments; data analysis and interpretation were performed by M. Jinushi, M. Sato, A. Kanamoto, A. Itoh, S. Nagai, S. Koyasu, G. Dranoff, and H. Tahara; and M. Jinushi, G. Dranoff, and H. Tahara prepared the manuscript.
###end p 56
###begin p 57
This study was supported in part by the Grants-in-Aid for Scientific Research on Priority Areas (20015016 to H. Tahara) and for Young Scientists (Start-Up; 20890050 to M. Jinushi) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, as well as by the Melanoma Research Alliance and the Research Foundation for the Treatment of Ovarian Cancer (G. Dranoff).
###end p 57
###begin p 58
The authors have no conflicting financial interests.
###end p 58
###begin article-title 59
Cytokines in cancer pathogenesis and cancer therapy.
###end article-title 59
###begin article-title 60
Paradoxical roles of the immune system during cancer development.
###end article-title 60
###begin article-title 61
Smoldering and polarized inflammation in the initiation and promotion of malignant disease.
###end article-title 61
###begin article-title 62
Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity.
###end article-title 62
###begin article-title 63
NF-kappaB: linking inflammation and immunity to cancer development and progression.
###end article-title 63
###begin article-title 64
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.
###end article-title 64
###begin article-title 65
Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88.
###end article-title 65
###begin article-title 66
Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.
###end article-title 66
###begin article-title 67
Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines.
###end article-title 67
###begin article-title 68
MFG-E8 mediated uptake of apoptotic cells by APCs links the pro- and anti-inflammatory activities of GM-CSF.
###end article-title 68
###begin article-title 69
Identification of a factor that links apoptotic cells to phagocytes.
###end article-title 69
###begin article-title 70
Milk fat globule EGF-8 promotes melanoma progression through coordinated Akt and Twist signaling in the tumor microenvironment.
###end article-title 70
###begin article-title 71
Melanoma.
###end article-title 71
###begin article-title 72
###xml 81 86 <span type="species:ncbi:10090">mouse</span>
MFG-E8/lactadherin promotes tumor growth in an angiogenesis-dependent transgenic mouse model of multistage carcinogenesis.
###end article-title 72
###begin article-title 73
###xml 100 115 <span type="species:ncbi:10090">transgenic mice</span>
Characterization of novel breast carcinoma-associated BA46-derived peptides in HLA-A2.1/D(b)-beta2m transgenic mice.
###end article-title 73
###begin article-title 74
Systemic therapy for colorectal cancer.
###end article-title 74
###begin article-title 75
###xml 91 97 <span type="species:ncbi:10090">murine</span>
Milk fat globule-EGF factor8/lactadherin plays a crucial role in maintenance and repair of murine intestinal epithelium.
###end article-title 75
###begin article-title 76
Lactadherin promotes VEGF-dependent neovascularization.
###end article-title 76
###begin article-title 77
###xml 78 82 <span type="species:ncbi:10090">mice</span>
Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice.
###end article-title 77
###begin article-title 78
Expression of milk fat globule epidermal growth factor 8 in immature dendritic cells for engulfment of apoptotic cells.
###end article-title 78
###begin article-title 79
Follicular dendritic cells control engulfment of apoptotic bodies by secreting Mfge8.
###end article-title 79
###begin article-title 80
Introduction of soluble protein into the class I pathway of antigen processing and presentation.
###end article-title 80
###begin article-title 81
Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo.
###end article-title 81
###begin article-title 82
Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells.
###end article-title 82
###begin article-title 83
Inflammation and cancer.
###end article-title 83
###begin article-title 84
Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies.
###end article-title 84
###begin article-title 85
Vascular endothelial growth factor: basic science and clinical progress.
###end article-title 85
###begin article-title 86
Clinical Approach to Infection in the Compromised Host.
###end article-title 86
###begin article-title 87
Ulcerative colitis and autoimmunity induced by loss of myeloid alphav integrins.
###end article-title 87
###begin article-title 88
Twist regulates cytokine gene expression through a negative feedback loop that represses NF-kappaB activity.
###end article-title 88
###begin article-title 89
Recruiting dendritic cells to improve antibody therapy of cancer.
###end article-title 89
###begin article-title 90
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
###end article-title 90
###begin article-title 91
###xml 133 141 <span type="species:ncbi:9606">patients</span>
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
###end article-title 91
###begin article-title 92
Calreticulin exposure dictates the immunogenicity of cancer cell death.
###end article-title 92
###begin article-title 93
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
###end article-title 93
###begin article-title 94
Immunogenic anti-cancer chemotherapy as an emerging concept.
###end article-title 94
###begin article-title 95
The DNA damage response arouses the immune system.
###end article-title 95
###begin article-title 96
###xml 37 41 <span type="species:ncbi:10090">mice</span>
Eradication of established tumors in mice by a combination antibody-based therapy.
###end article-title 96
###begin article-title 97
The TRAIL apoptotic pathway in cancer onset, progression and therapy.
###end article-title 97
###begin article-title 98
Systemic administration of Il-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12.
###end article-title 98
###begin article-title 99
T cell receptor antagonist peptides induce positive selection.
###end article-title 99
###begin article-title 100
###xml 62 68 <span type="species:ncbi:10090">murine</span>
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
###end article-title 100
###begin p 101
Abbreviations used: 5-FU, 5-fluorouracil; BMDC, bone marrow-derived dendritic cell; MFG-E8, milk fat globule epidermal growth factor-8; NOD-SCID, nonobese diabetic-severe combined immunodeficiency; VEGFR-2, antivascular endothelial growth factor receptor-2.
###end p 101

